Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety

István Laszlovszky, Ágota Barabássy, György Németh, István Laszlovszky, Ágota Barabássy, György Németh

Abstract

Schizophrenia is characterized by positive, negative, cognitive, and affective symptoms. Antipsychotic medications, which work by blocking the dopamine D2 receptor, are the foundation of pharmacotherapy for schizophrenia to control positive symptoms. Cariprazine is a dopamine D3 receptor-preferring D3/D2 partial agonist antipsychotic that is approved for the treatment of schizophrenia (USA and European Union [EU]) and manic and depressive episodes associated with bipolar I disorder (USA). Partial agonist agents have a lower intrinsic activity at receptors than full agonists, so they act as either functional agonists or functional antagonists depending on the surrounding neurotransmitter environment. Beyond efficacy against positive symptoms, the unique D3-preferring partial agonist pharmacology of cariprazine suggests potential advantages against negative symptoms, and cognitive and functional impairment, which are challenging to treat. The efficacy and safety of cariprazine in adult patients with schizophrenia have been demonstrated in four short-term randomized, double-blind, placebo-controlled clinical trials, two long-term open-label studies, one relapse prevention study, and one prospective negative symptom study versus the active comparator risperidone. Additional post hoc investigations have supported efficacy across individual symptoms and domains in schizophrenia, as well as in diverse areas of interest including cognition, functioning, negative symptoms, hostility, and global well-being. This comprehensive review of cariprazine summarizes its pharmacologic profile, clinical trial evidence, and post hoc investigations. Collective evidence suggests that the pharmacology of cariprazine may offer broad-spectrum efficacy advantages for patients with schizophrenia, including effects against difficult-to-treat negative and cognitive symptoms, as well as functional improvements. Cariprazine was generally safe and well tolerated in patients with short- and long-term exposure and no new safety concerns were associated with longer-duration treatment.Trial registration ClinicalTrials.gov identifiers, NCT00404573, NCT00694707, NCT01104766, NCT01104779, NCT01412060, NCT00839852, NCT01104792.

Keywords: Atypical antipsychotic; Cariprazine; Dopamine D2 receptor; Dopamine D3 receptor; Functional improvement; Partial agonist; Predominant negative symptoms; Schizophrenia.

© 2021. The Author(s).

References

    1. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19–28. doi: 10.1001/archpsyc.64.1.19.
    1. Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(Pt C):168–176. doi: 10.1016/j.pnpbp.2017.06.031.
    1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97. doi: 10.1016/S0140-6736(15)01121-6.
    1. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303–318. doi: 10.1177/2045125318781475.
    1. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–193. doi: 10.1038/nature09552.
    1. Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry. 2012;27(6):432–436. doi: 10.1016/j.eurpsy.2011.02.015.
    1. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150(2–3):339–342. doi: 10.1016/j.schres.2013.07.014.
    1. Suttajit S, Pilakanta S. Predictors of quality of life among individuals with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:1371–1379. doi: 10.2147/NDT.S81024.
    1. Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777. doi: 10.2147/TCRM.S117321.
    1. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268–274. doi: 10.4088/PCC.v07n0602.
    1. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12–21. doi: 10.1016/S0924-9338(10)71701-6.
    1. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr. 2004;9(10 Suppl 11):6–14. doi: 10.1017/S1092852900025086.
    1. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. doi: 10.1016/S0140-6736(08)61764-X.
    1. Chow CL, Kadouh NK, Bostwick JR, VandenBerg AM. Akathisia and newer second-generation antipsychotic drugs: a review of current evidence. Pharmacotherapy. 2020;40(6):565–574. doi: 10.1002/phar.2404.
    1. Rauly-Lestienne I, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Cussac D. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol. 2007;376(1–2):93–105. doi: 10.1007/s00210-007-0182-6.
    1. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251–267. doi: 10.2165/00023210-200418040-00005.
    1. Casey AB, Canal CE. Classics in chemical neuroscience: aripiprazole. ACS Chem Neurosci. 2017;8(6):1135–1146. doi: 10.1021/acschemneuro.7b00087.
    1. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–340. doi: 10.1124/jpet.109.160432.
    1. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347(6289):146–151. doi: 10.1038/347146a0.
    1. Sokoloff P, Le Foll B. The dopamine D3 receptor, a quarter century later. Eur J Neurosci. 2017;45(1):2–19. doi: 10.1111/ejn.13390.
    1. Agai-Csongor E, Domány G, Nógrádi K, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012;22(10):3437–3440. doi: 10.1016/j.bmcl.2012.03.104.
    1. Calabrese F, Tarazi FI, Racagni G, Riva MA. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020;25(3):343–351. doi: 10.1017/S109285291900083X.
    1. Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21(2):123–127. doi: 10.1017/S1092852916000043.
    1. Girgis RR, Slifstein M, D'Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. 2016;233(19–20):3503–3512. doi: 10.1007/s00213-016-4382-y.
    1. Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925–935. doi: 10.1016/j.neuint.2011.07.002.
    1. Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017;20(10):788–796. doi: 10.1093/ijnp/pyx038.
    1. Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology. 2013;226(1):91–100. doi: 10.1007/s00213-012-2896-5.
    1. Laszlovszky I, Gage A, Kapas M, Ghahramani P. Characterization of cariprazine (RGH-188) D3/D2 receptor occupancy in healthy volunteers and schizophrenic patients by positron emission tomography (PET) Eur Psychiatry. 2010;25(S1):1.
    1. Girgis R, Abi-Dargham A, Slifstein M, et al. In vivo dopamine D3 and D2 receptor occupancy profile of cariprazine versus aripiprazole: a PET study. Neuropsychopharmacology. 2017;42:S595.
    1. Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology. 2020;45(5):786–792. doi: 10.1038/s41386-019-0590-6.
    1. Mizrahi R, Agid O, Borlido C, et al. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res. 2011;131(1–3):63–68. doi: 10.1016/j.schres.2011.05.005.
    1. Gyertyán I, Sághy K, Laszy J, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):529–539. doi: 10.1007/s00210-008-0311-x.
    1. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005;10(13):917–925. doi: 10.1016/S1359-6446(05)03491-4.
    1. Kiss B, Laszlovszky I, Horváth A, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):515–528. doi: 10.1007/s00210-008-0308-5.
    1. Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology. 2005;179(3):567–575. doi: 10.1007/s00213-004-2096-z.
    1. Leggio GM, Salomone S, Bucolo C, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013;719(1–3):25–33. doi: 10.1016/j.ejphar.2013.07.022.
    1. Kiss B, Némethy Z, Fazekas K, et al. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Drug Des Devel Ther. 2019;13:3229–3248. doi: 10.2147/DDDT.S188760.
    1. Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) Drug Des Devel Ther. 2016;10:327–338. doi: 10.2147/DDDT.S95100.
    1. Reagila SPC. Reagila [Summary of Product Characteristics]. Update 06/25/2018. . Accessed 4 May 2021
    1. Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–e1582. doi: 10.4088/JCP.15m09997.
    1. Durgam S, Litman RE, Papadakis K, et al. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2016;31(2):61–68. doi: 10.1097/YIC.0000000000000110.
    1. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–457. doi: 10.1016/j.schres.2013.11.041.
    1. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–373. doi: 10.1097/JCP.0000000000000346.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261.
    1. Guy W. The Clinical Global Impression Severity and Improvement Scales. ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication (ADM). 76–338. Rockville, MD: National Institute of Mental Health; 1976:218–222.
    1. Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2–3):264–271. doi: 10.1016/j.schres.2016.06.030.
    1. Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013;150(2–3):346–352. doi: 10.1016/j.schres.2013.07.026.
    1. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013–1022. doi: 10.1093/schbul/sbl057.
    1. Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113. doi: 10.1016/S0140-6736(17)30060-0.
    1. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538–546. doi: 10.4088/JCP.v58n1205.
    1. Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161(2):213–224. doi: 10.1016/j.psychres.2007.11.012.
    1. Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525–1535. doi: 10.2147/NDT.S201726.
    1. Marder S, Fleischhacker WW, Earley W, et al. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019;29(1):127–136. doi: 10.1016/j.euroneuro.2018.10.008.
    1. Volavka J, Czobor P, Derks EM, et al. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST) J Clin Psychiatry. 2011;72(7):955–961. doi: 10.4088/JCP.10m06529.
    1. Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016;77(1):109–115. doi: 10.4088/JCP.15m10192.
    1. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4(7):28–37.
    1. Durgam S, Earley W, Lu K, et al. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis. Int J Clin Pract. 2017;71(12):e13037. doi: 10.1111/ijcp.13037.
    1. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. doi: 10.1002/wps.20060.
    1. Correll CU, Potkin SG, Zhong Y, et al. Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. J Clin Psychiatry. 2019;80(2):1. doi: 10.4088/JCP.18m12495.
    1. Correll CU, Jain R, Meyer JM, et al. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat. 2019;15:2537–2550. doi: 10.2147/NDT.S210340.
    1. Earley W, Guo H, Daniel D, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr Res. 2019;204:282–288. doi: 10.1016/j.schres.2018.08.020.
    1. Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9. doi: 10.1016/j.eurpsy.2019.01.015.
    1. Laszlovszky I, Kiss B, Barabássy Á, et al. Cognitive improving properties of cariprazine, a dopamine D3 receptor preferring partial agonist: overview of non-clinical and clinical data. Eur Psychiatry. 2019;56(Suppl):S238.
    1. Cutler AJ, Durgam S, Wang Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23(1):39–50. doi: 10.1017/S1092852917000220.
    1. Durgam S, Greenberg WM, Li D, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017;234(2):199–209. doi: 10.1007/s00213-016-4450-3.
    1. McEvoy J, Earley W, Guo H, Szatmári B, Hostetler C. Long-term effects of cariprazine in patients with negative symptoms of schizophrenia: a post hoc analysis of two 48-week, open-label studies. Poster presented at the 171st Annual Meeting of the American Psychiatric Association; New York, NY; May 5–9; 2018.
    1. Gkintoni E, Pallis EG, Bitsios P, Giakoumaki SG. Neurocognitive performance, psychopathology and social functioning in individuals at high risk for schizophrenia or psychotic bipolar disorder. J Affect Disord. 2017;208:512–520. doi: 10.1016/j.jad.2016.10.032.
    1. Kuswanto C, Chin R, Sum MY, et al. Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: Whither the evidence? Neurosci Biobehav Rev. 2016;61:66–89. doi: 10.1016/j.neubiorev.2015.12.002.
    1. Fleischhacker WW, Marder S, Lu K, et al. Efficacy of cariprazine versus placebo across schizophrenia symptom domains: pooled analyses from 3 phase II/III trials. Poster presented at the annual meeting of the American Society of Clinical Psychopharmacology; Miami, Florida; June 22–25, 2015
    1. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry. 1991;6(2):95–102. doi: 10.1002/gps.930060208.
    1. Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousono M. Quality of life in schizophrenic patients. Dialogues Clin Neurosci. 2007;9(2):215–226. doi: 10.31887/DCNS.2007.9.2/jbobes.
    1. Martin CR, Allan R. Factor structure of the schizophrenia quality of life scale revision 4 (SQLS-R4) Psychol Health Med. 2007;12(2):126–134. doi: 10.1080/13548500500407383.
    1. Kahn R, Earley W, Kaifeng L, et al. Effects of cariprazine on health-related quality of life in patients with schizophrenia. Poster presented at the Annual Meeting of the American Psychiatric Association; Toronto, Ontario, Canada; May 16–20, 2015.
    1. Cutler AJ, Durgam S, Lu K, Laszlovszky I, Earley W. Post hoc analysis of a randomized, controlled trial. Poster presented at the 169th Annual Meeting of the American Psychiatric Association; Atlanta, Georgia; May 14–18, 2016
    1. Laszlovszky I, Acsai K, Barabássy Á, et al. Long-term functional improving effects of cariprazine: Post-hoc analyses of acute and predominant negative symptom schizophrenia patient data. Eur Neuropsychopharmacol. 2020;40(Suppl 1):S326–S327. doi: 10.1016/j.euroneuro.2020.09.421.
    1. Mofsen RS, Xu S, Németh G, et al. Efficacy of cariprazine by baseline symptom severity in patients with schizophrenia: A post hoc analysis of 3 randomized controlled trials. Poster presented at the 170th Annual Meeting of the American Psychiatric Association; San Diego, CA; May 20–24, 2017
    1. Mofsen R, Chang C-T, Németh G, Barabássy Á, Earley W. Efficacy of cariprazine in patients with schizophrenia based on stage of illness. Presented at the Biennial International Congress on Schizophrenia Research; San Diego, California, March 24–28, 2017
    1. Earley W, Durgam S, Lu K, et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32(6):319–328. doi: 10.1097/YIC.0000000000000187.
    1. Nasrallah HA, Earley W, Cutler AJ, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17(1):305. doi: 10.1186/s12888-017-1459-z.
    1. Barabássy Á, Sebe B, Acsai K, et al. Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II/III studies. Neuropsychiatr Dis Treat. 2021;17:957–970. doi: 10.2147/NDT.S301225.
    1. Barabássy Á, Sebe B, Szatmári B, et al. Akathisia during cariprazine treatment: post-hoc analyses of pooled schizophrenia studies. Eur Neuropsychopharmacol. 2019;29(Suppl 6):S323.
    1. European Medicines Agency. Assessment Report. Reagila. . Accessed 11 Mar 2021.
    1. Sebe B, Barabássy Á, Szatmári B, et al. Short- and long-term changes in metabolic parameters and body weight in cariprazine-treated patients with schizophrenia. Eur Psychiatry. 2019;56(1):S824.
    1. Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring. J Am Heart Assoc. 2016;5(6):e003264. doi: 10.1161/JAHA.116.003264.
    1. Barabassy Á, Sebe B, Laszlovszky I, et al. Cardiac safety with cariprazine treatment. Eur Psychiatry. 2020;63(S1):S252–S253.
    1. Szatmári B, Barabássy Á, Laszlovszky I, et al. Safety profile of cariprazine: post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies. Eur Neuropsychopharmacol. 2018;29(Suppl 1):S419.
    1. Barabássy Á, Szatmári B, Laszlovszky I, et al. Hormonal effects of cariprazine: post hoc analysis of pooled data from schizophrenia studies for sexual dysfunction and prolactin changes. Eur Psychiatry. 2018;48(Suppl):S701.
    1. Keks N, Hope J, Schwartz D, et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020;34(5):473–507. doi: 10.1007/s40263-020-00718-4.
    1. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3.
    1. Fagiolini A, Alcalá J, Aubel T, et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel. Ann Gen Psychiatry. 2020;19:55. doi: 10.1186/s12991-020-00305-3.
    1. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. doi: 10.3109/15622975.2012.739708.
    1. Vita A, Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018;31(3):246–255. doi: 10.1097/YCO.0000000000000407.
    1. Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36(4):355–371. doi: 10.1097/JCP.0000000000000523.
    1. Vraylar US label. Vraylar [package insert]. Madison, NJ: Allergan USA, Inc. Revised 2019.
    1. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. doi: 10.1016/S2215-0366(19)30416-X.
    1. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull. 2011;37(2):250–254. doi: 10.1093/schbul/sbq161.
    1. Leucht S, Barabássy Á, Laszlovszky I, et al. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. Neuropsychopharmacology. 2019;44(9):1589–1596. doi: 10.1038/s41386-019-0363-2.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren